It is always a challenge to comment on an article which attempts to draw together topics as complex and diverse as: the role of psychodynamic therapy in war time soldiers; the role of the asylum in western history; the Harrison Narcotics act of 1914; the Food Drugs and Cosmetics Act; the role of contraception in social change; the Enlightenment; the efficacy and image of ECT in medicine and the lay public; the evolution of our understanding of tardive dyskinesia; the role of clinical trials in medicine and drug development; the "politics" of psychopharmacology; publication bias; changes in popular psychology over the last 50 years; drug dependence; deinstitutionalization; "corporate psychiatry"; "Big Science"; the development of receptor assay technology; the role of psychological testing in establishing societal and medical "norms"; the differences between managing the risk factors for a disease and the disease itself; pharmaceutical and other corporate marketing; the relationship between the pharmaceutical industry and academia; the justifications for pediatric psychopharmacology; the epidemiology of eating disorders; -to mention only some.
In my experience, when one attempts to draw together so many disparate and complex issues in a ten-page paper, it is likely that some lapses in rigor will occur. In some such situations, what might appear initially and superficially to be "scholarly," rapidly becomes what would more appropriately be labeled as "intellectually irresponsible". So in the midst of all of this, we find statements such as "clinical trials in psychiatry, however, have never shown that anything worked". I pray that it is not only cognitive dissonance that leads me reject such a statement.
Another example, " w hen the new (am sychotic) drugs came, starting with clozapi they came not because they were better d the older drugs, but rather because clozap didn't cause tardive dyskinesia". As sor one who was intimately involved in clinical development and FDA approval clozapine, I would point out that clozapii low propensity to cause tardive dyskini was not a major factor in leading to approval (and has not been a major is in the "marketing" G f clozapine either I cite these as but examples. The aut certainly touches on areas where clc scrutiny and further scientific debate critical. One could certainly complim the author on his broad range of interi and the ambitiousness of his review; h( ever, it ultimately fails as a vehicle informing the reader or enhancing app priate debate.
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